Zhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline
- Extending the Cooperation in Pulmonary Arterial Hypertension
News provided by
Share this article
Share this article
SHANGHAI, Mar. 17, 2021 /PRNewswire/ Zhongchao Inc. (NASDAQ: ZCMD) ( Zhongchao or the Company ), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced the renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education program Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals ( PAH Project ) in 2021.
The PAH Project aims to promote the implementation of the multidisciplinary treatment model of pulmonary hypertension and improve doctors ability to solve clinical problems. In 2020, more than 200 experts in pulmonary hyp
Share this article
Share this article
SHANGHAI, Jan. 13, 2021 /PRNewswire/ Zhongchao Inc. (NASDAQ: ZCMD) ( Zhongchao or the Company ), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it co-sponsored the National Annual Conference for Standardized Liver Cancer Diagnosis and Treatment (the Annual Conference ) with China Association of Health Promotion and Education and Chinese Society of Liver Cancer.
In 2020, Zhongchao worked with medical associations and experts to jointly carry out a multi-year online education project on the diagnosis and treatment of primary liver cancer. This project aims to promote and implement the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition) (the Guidelines ) published by the National Health Commission of the People s Republic of China. Based on the professional interpretation and through its online
José M. Vega, M.D. Joins Moderna as Chief Safety Officer
José M. Vega, M.D. Joins Moderna as Chief Safety Officer
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Jos M. Vega, M.D. joined Moderna as Chief Safety Officer effective Monday, January 11, 2021. Dr. Vega will report to Chief Medical Officer Tal Zaks, M.D., Ph.D. Jos brings a strategic level of leadership and deep experience in drug development and pharmacovigilance in global biopharmaceutical companies including Merck and Amgen, said Dr. Zaks. I am thrilled to welcome Jos to the Moderna team as we enter the next phase of growth of our company.